Gastroenteropancreatic Neuroendocrine Tumors Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

Posted on
by

Gastroenteropancreatic Neuroendocrine Tumors Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover the gastrointestinal neuroendocrine tumors’ new treatment @ https://www.delveinsight.com/sample-request/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market

Key Takeaways from the Gastroenteropancreatic Neuroendocrine Tumors Market Report

  • On February 03, 2026- Novartis Pharmaceuticals announced a study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 <10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden.
  • GEP-NETs represent the second most common digestive cancer in terms of prevalence.
  • According to findings, small intestine (30.8%), rectum (26.3%), colon (17.6%), pancreas (12.1%), and appendix (5.7%) are the most common primary NET sites in the digestive tract.
  • According to the findings, 53% of patients with NETs present with localized disease, 20% have locoregional disease, and 27% have distant metastases at the time of diagnosis.
  • The old age population is more susceptible to suffering from Gastroenteropancreatic NET.
  • The leading Gastroenteropancreatic Neuroendocrine Tumors Companies such as ITM Solucin GmbH, Camurus, Bristol Myers Squibb, RayzeBio, and others.
  • Promising Gastroenteropancreatic Neuroendocrine Tumors Therapies such as ITM-11 (n.c.a. 177Lu-edotreotide), CAM2029, RYZ101 (Actinium-225 DOTATATE), and others.

To know more about gastrointestinal neuroendocrine tumors treatment options, visit @ Approved Gastrointestinal Neuroendocrine Tumors Drugs

Gastroenteropancreatic Neuroendocrine Tumors Overview

Neuroendocrine tumors (NETs) are heterogeneous neoplasms arising in secretory cells of the diffuse neuroendocrine system. They are characterized by a relatively indolent growth and the ability to secrete biogenic amines and peptide hormones. Gastroenteropancreatic NETs (GEP-NETs) include NETs of the gastrointestinal tract (GI-NETs) and pancreatic NETs (panNETs) and can be subdivided into well-differentiated (low-, intermediate- or high-grade) tumors and poorly differentiated carcinomas (NECs), according to their morphology and proliferative activity.

Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Segmentation in the 7MM

  • Total Incident Cases
  • Grade-specific Cases
  • Tumor site-specific Cases
  • Stage-specific Cases
  • Symptom-specific Cases

Discover more about therapy for Gastrointestinal Neuroendocrine Tumors @ Gastrointestinal Neuroendocrine Tumors Clinical Trials

Gastroenteropancreatic NET Marketed Drugs

  • LUTATHERA: Novartis

Lutathera (lutetium Lu 177 dotatate*) is a lutetium Lu 177-labeled somatostatin analog peptide. Lutathera belongs to a class of treatments called Peptide Receptor Radionuclide Therapy (PRRT). Lutathera is comprised of a targeting molecule that carries a radioactive component. Lutathera has received orphan drug designation from the FDA and the European Medicines Agency (EMA). It was approved in 2018 by the US FDA for the treatment of adult patients with SSTR-positive GEP-NETs, including those in the foregut, midgut, and hindgut. Lutathera is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptors (SSTR)-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs.

  • SOMATULINE DEPOT: Ipsen Biopharmaceuticals

SOMATULINE DEPOT (lanreotide) is a somatostatin analog indicated for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Emerging Gastroenteropancreatic NET Drugs

  • CAM2029: Camurus AB

CAM2029 is a long-acting octreotide subcutaneous depot under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market-leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen. CAM2029 is based on Camurus’ proprietary FluidCrystal technology. Currently, it is in Phase III of clinical development for the treatment of GEP-NET.

  • ITM-11: ITM Isotope Technologies Munich

ITM-11 (177Lu-edotreotide), being developed by ITM Isotope Technologies Munich, is an innovative Targeted Radionuclide Therapy agent consisting of two components: firstly, Edotreotide (DOTATOC), an octreotide-derived somatostatin analog, and secondly, EndolucinBeta (no-carrier-added (n.c.a.) lutetium-177 chloride) a synthetic, low-energy beta-emitting therapeutic radioisotope.. It is currently being investigated in two Phase III clinical trials, COMPETE (NCT03049189) and COMPOSE (NCT04919226). While COMPETE is evaluating ITM-11 for the treatment of patients with grade 1 and grade 2 GEP-NETs, the radiopharmaceutical candidate is also being investigated in COMPOSE, for patients with well-differentiated high grade 2 and grade 3 GEP-NETs. ITM-11 received an orphan designation as a treatment for GEP-NETs based on the data from a Phase II clinical study, which demonstrated a significant benefit (substantially improved progression-free survival, PFS).

Download the report to understand which factors are driving gastrointestinal neuroendocrine tumors therapeutics market trends @ Gastrointestinal Neuroendocrine Tumors Market Trends

Gastroenteropancreatic Neuroendocrine Tumors Therapies and Companies

  • ITM-11: ITM Isotope Technologies Munich
  • CAM2029: Camurus AB

Gastroenteropancreatic Neuroendocrine Tumors Market Strengths

  • The development of novel targeted therapies and personalized treatment options has enhanced the treatment efficacy and outcomes for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), strengthening the market.
  • Improved diagnostic tools and imaging technologies, coupled with rising awareness, allow for early detection and diagnosis of GEP-NETs, driving market growth.

Gastroenteropancreatic Neuroendocrine Tumors Market Opportunities

  • The growing pipeline of therapies, including immunotherapies and new targeted agents, offers significant opportunities for market expansion and improved treatment outcomes for GEP-NET patients.
  • The shift toward precision medicine and personalized treatments tailored to genetic profiles and tumor characteristics presents a major opportunity for the GEP-NET market, allowing for more effective management of the disease.

Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM
  • Gastroenteropancreatic Neuroendocrine Tumors Companies: Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien München, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
  • Gastroenteropancreatic Neuroendocrine Tumors Therapies: ITM-11, CAM2029, and others.
  • Gastroenteropancreatic Neuroendocrine Tumors Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumors current marketed and Gastroenteropancreatic Neuroendocrine Tumors emerging therapies
  • Gastroenteropancreatic Neuroendocrine Tumors Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumors market drivers and Gastroenteropancreatic Neuroendocrine Tumors market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL’s views, Analyst’s views, Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement

To learn more about Gastroenteropancreatic Neuroendocrine Tumors companies working in the treatment market, visit @ GEP-NETs Clinical Trials and Therapeutic Assessment

Table of Contents

1. Gastroenteropancreatic Neuroendocrine Tumors Market Report Introduction

2. Executive Summary for Gastroenteropancreatic Neuroendocrine Tumors

3. SWOT analysis of Gastroenteropancreatic Neuroendocrine Tumors

4. Gastroenteropancreatic Neuroendocrine Tumors Patient Share (%) Overview at a Glance

5. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance

6. Gastroenteropancreatic Neuroendocrine Tumors Disease Background and Overview

7. Gastroenteropancreatic Neuroendocrine Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroenteropancreatic Neuroendocrine Tumors

9. Gastroenteropancreatic Neuroendocrine Tumors Current Treatment and Medical Practices

10. Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs

11. Gastroenteropancreatic Neuroendocrine Tumors Emerging Therapies

12. Gastroenteropancreatic Neuroendocrine Tumors Market Outlook

13. Country-Wise Gastroenteropancreatic Neuroendocrine Tumors Market Analysis (2020–2034)

14. Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement of Therapies

15. Gastroenteropancreatic Neuroendocrine Tumors Market Drivers

16. Gastroenteropancreatic Neuroendocrine Tumors Market Barriers

17. Gastroenteropancreatic Neuroendocrine Tumors Appendix

18. Gastroenteropancreatic Neuroendocrine Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market